Five Under 5: Top Oncology Videos for the Week of 2/1

Welcome to The Five Under 5, your go-to roundup of the top 5 videos of the week.

These short videos are designed for busy oncologists to view on the go, and feature expert insights on breaking news, regulatory updates, practice-changing data shared at medical meetings, and other key topics in the realm of oncology.

Here’s what you may have missed:

Role of Molecular and Genetic Testing in Ph+ Acute Lymphoblastic Leukemia: Nicholas J. Short, MD

Nicholas James Short, MD, of The University of Texas MD Anderson Cancer Center, discussed how molecular and genetic testing informs management of relapsed Philadelphia chromosome–positive acute lymphoblastic leukemia. He explained that although BCR-ABL1 kinase domain mutation testing is biologically informative after relapse on imatinib (Gleevec) or dasatinib (Sprycel), mutation status often does not change immediate treatment decisions. In relapsed disease, Short underscored the need to escalate promptly to the most potent available therapy, favoring ponatinib (Iclusig) even in the absence of detectable T315I mutations. He also noted ongoing clinical trials examining next-generation agents like asciminib (Scemblix) and olverembatinib (HQP1351).

Factors That Influence Treatment Sequencing With ADCs in Breast Cancer: David L. Rimm, MD, PhD

David Rimm, MD, PhD, of Yale School of Medicine and Yale Cancer Center, discussed the importance of precision target measurement and strategic sequencing of antibody-drug conjugates (ADCs) in breast cancer. He framed ADCs as targeted therapies and highlighted his laboratory’s work quantifying targets using attomoles per square millimeter to better predict treatment response. Rimm noted that as several ADCs become available, oncologists will increasingly face decisions about which agent to use first, despite limited evidence guiding sequencing strategies. He pointed to the phase 2 TRADE-DXd trial (NCT06533826) as a key piece of research that may clarify optimal ADC sequencing and the role of intercalated chemotherapy.

Benefits of Up-front Dose Reduction for Enfortumab Vedotin in Urothelial Cancer: Ryan D. Chow, MD

Ryan D. Chow, MD, of Penn Medicine at the University of Pennsylvania Health System, unpacked real-world findings examining up-front dose reduction of enfortumab vedotin-ejfv (Padcev) when combined with pembrolizumab (Keytruda) in urothelial cancer. He reported that patients who started at a reduced dose experienced significantly fewer treatment interruptions without compromising overall survival. This benefit was maintained in older and physiologically vulnerable patients, including those with poor renal function or an ECOG performance status of 2 or higher. Chow concluded that up-front dose reduction could offer a more tolerable and sustainable strategy while preserving efficacy in routine clinical practice.

Updated OS Data With Relacorilant Plus Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer: Alexander B. Olawaiye, MD

Alexander B. Olawaiye, MD, of Magee-Women’s Hospital of the University of Pittsburgh Medical Center, discusses updated survival results from the phase 3 ROSELLA trial (NCT05257408) assessing relacorilant plus nab-paclitaxel (Abraxane) in platinum-resistant ovarian cancer. He noted that the trial met both coprimary end points of progression-free survival (PFS) and overall survival (OS). The combination improved median OS to 16.0 months compared with 11.9 months with nab-paclitaxel alone, translating to a 35% reduction in the risk of death. Olawaiye explained that relacorilant is a selective glucocorticoid receptor antagonist designed to modulate cortisol signaling without affecting other hormone receptors.

Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma: Peter Riedell, MD

Peter Riedell, MD, of the University of Chicago Comprehensive Cancer Center, spotlighted 5-year landmark findings from the phase 2 ELARA trial (NCT03568461) examining tisagenlecleucel (Kymriah) in patients with relapsed/refractory follicular lymphoma. He discussed the durability of responses, with a median PFS of 53.2 months following a single CAR T-cell infusion. Riedell emphasized that no disease progression was observed beyond 36 months among patients who remained in response at that time. These data, he concluded, solidify the role of CAR T-cell therapy as an effective third-line option with potential for long-term remission.